OptimizeRx Names Stephen Silverstro as Interim CEO, Sees FY24 Revenue At High End of Guidance Range

MT Newswires Live

2024/12/23

OptimizeRx (OPRX) said Monday that Chief Executive William J. Febbo will leave the company, effective Dec. 31 and that it appointed Stephen Silvestro as interim CEO.

The digital health technology company said its board hired a search firm to assist in the transition and to help look for a successor. Silvestro was the company's chief commercial officer before becoming president last year, OptimizeRx said.

OptimizeRx said it expects full-year 2024 revenue to come in at the higher end of the $88 million to $92 million guidance range.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2493765571"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2493765571\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2493765571?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-23 22:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493765571","market":"sh","top_or_hot":-1,"title":"OptimizeRx Names Stephen Silverstro as Interim CEO, Sees FY24 Revenue At High End of Guidance Range","media":"MT Newswires Live","content":"<html><body><p> OptimizeRx (OPRX) said Monday that Chief Executive William J. Febbo will leave the company, effective Dec. 31 and that it appointed Stephen Silvestro as interim CEO.</p><p>The digital health technology company said its board hired a search firm to assist in the transition and to help look for a successor. Silvestro was the company's chief commercial officer before becoming president last year, OptimizeRx said.</p><p>OptimizeRx said it expects full-year 2024 revenue to come in at the higher end of the $88 million to $92 million guidance range.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OptimizeRx Names Stephen Silverstro as Interim CEO, Sees FY24 Revenue At High End of Guidance Range</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOptimizeRx Names Stephen Silverstro as Interim CEO, Sees FY24 Revenue At High End of Guidance Range\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-12-23 22:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> OptimizeRx (OPRX) said Monday that Chief Executive William J. Febbo will leave the company, effective Dec. 31 and that it appointed Stephen Silvestro as interim CEO.</p><p>The digital health technology company said its board hired a search firm to assist in the transition and to help look for a successor. Silvestro was the company's chief commercial officer before becoming president last year, OptimizeRx said.</p><p>OptimizeRx said it expects full-year 2024 revenue to come in at the higher end of the $88 million to $92 million guidance range.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OPRX","symbol_name":"OptimizeRx Corporation","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2493765571","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493765571","pubTimestamp":1734964314,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"OptimizeRx  said Monday that Chief Executive William J. Febbo will leave the company, effective Dec. 31 and that it appointed Stephen Silvestro as interim CEO.The digital health technology company said its board hired a search firm to assist in the transition and to help look for a successor. Silvestro was the company's chief commercial officer before becoming president last year, OptimizeRx said.OptimizeRx said it expects full-year 2024 revenue to come in at the higher end of the $88 million to $92 million guidance range.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"OPRX":"OptimizeRx Corporation"},"translate_title":"OptimizeRx任命Stephen Silverstro为临时首席执行官，预计2024财年收入处于指导范围的高端","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPRX":0.9},"content_text":"OptimizeRx (OPRX) said Monday that Chief Executive William J. Febbo will leave the company, effective Dec. 31 and that it appointed Stephen Silvestro as interim CEO.The digital health technology company said its board hired a search firm to assist in the transition and to help look for a successor. Silvestro was the company's chief commercial officer before becoming president last year, OptimizeRx said.OptimizeRx said it expects full-year 2024 revenue to come in at the higher end of the $88 million to $92 million guidance range.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}